Kaya Kadir, Gevher Özlem
Department of Dermatology, Şanlıurfa Training and Research Hospital, Şanlıurfa, Turkey.
Department of Dermatology, Mehmet Akif İnan Training and Research Hospital, Şanlıurfa, Turkey.
Cutan Ocul Toxicol. 2024 Dec;43(4):253-257. doi: 10.1080/15569527.2024.2387595. Epub 2024 Aug 11.
OBJECTIVE: Hidradenitis suppurativa (HS), a chronic inflammatory disease that typically manifests after puberty, is characterised by painful nodules, abscesses, draining sinus tracts, and scars in areas rich in apocrine glands such as the axillary and inguinal regions. In recent years, blood-based biomarkers such as the Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR), Monocyte/Lymphocyte Ratio (MLR), Mean Platelet Volume (MPV), Systemic Immune-Inflammation Index (SII) and Pan-Immune-Inflammation Value (PIV) have been used as significant indicators of systemic inflammation. While there are few studies evaluating these biomarkers in HS, the response of these markers to treatment has only been assessed in one study to date. Our study aims to investigate the effect of adalimumab treatment on blood-based systemic inflammation biomarkers in HS, where inflammation plays a significant role. METHODS: The study included 42 adult patients who received adalimumab treatment at our dermatology and venereology clinic between January 2020 and January 2023. Medical records for complete blood count results of the patients were retrospectively reviewed. All systemic inflammation-based biomarkers were calculated from the absolute values of the complete blood count. The SII was calculated with the following formula: (neutrophil count × platelet count/lymphocyte count). The PIV was calculated as follows: (neutrophil count × platelet count × monocyte count/lymphocyte count). Values before the treatment and at the 12th week of treatment were compared. RESULTS: When the changes in the inflammatory parameters of the patients were examined, it was found that NLR (2.13 ± 0.87 vs 2.26 ± 1.12), PLR (111.01 ± 39.89 vs 99.43 ± 35.34), MLR (0.27 ± 0.11 vs 0.28 ± 0.12), MPV (9.59 ± 0.71 vs 9.70 ± 0.79), SII (680.79 ± 330.18 vs 687.89 ± 442.66), and PIV (552.02 ± 330.71 vs 605.05 ± 415.96) values did not change statistically significantly after treatment (p > 0.05). While there was a significant decrease in platelet count compared to before treatment, no statistically significant difference was found in the other evaluated blood cells. CONCLUSION: Adalimumab treatment has not had a significant effect on systemic inflammation markers in HS, an inflammatory disease. More studies are needed to evaluate the effect of adalimumab on these markers in HS.
目的：化脓性汗腺炎（HS）是一种通常在青春期后出现的慢性炎症性疾病，其特征为在富含顶泌汗腺的区域（如腋窝和腹股沟区）出现疼痛性结节、脓肿、引流性窦道和瘢痕。近年来，基于血液的生物标志物，如中性粒细胞/淋巴细胞比值（NLR）、血小板/淋巴细胞比值（PLR）、单核细胞/淋巴细胞比值（MLR）、平均血小板体积（MPV）、全身免疫炎症指数（SII）和全免疫炎症值（PIV），已被用作全身炎症的重要指标。虽然评估这些生物标志物在HS中的研究较少，但迄今为止仅有一项研究评估了这些标志物对治疗的反应。我们的研究旨在调查阿达木单抗治疗对HS中基于血液的全身炎症生物标志物的影响，在HS中炎症起着重要作用。 方法：该研究纳入了2020年1月至2023年1月期间在我们皮肤科和性病科诊所接受阿达木单抗治疗的42例成年患者。回顾性审查患者全血细胞计数结果的病历。所有基于全身炎症的生物标志物均根据全血细胞计数的绝对值计算。SII的计算公式如下：（中性粒细胞计数×血小板计数/淋巴细胞计数）。PIV的计算方法如下：（中性粒细胞计数×血小板计数×单核细胞计数/淋巴细胞计数）。比较治疗前和治疗第12周时的值。 结果：检查患者炎症参数的变化时发现，治疗后NLR（2.13±0.87 vs 2.26±1.12）、PLR（111.01±39.89 vs 99.43±35.34）、MLR（0.27±0.11 vs 0.28±0.12）、MPV（9.59±0.71 vs 9.70±0.79）、SII（680.79±330.18 vs 687.89±442.66）和PIV（552.02±330.71 vs 605.05±415.96）值无统计学显著变化（p>0.05）。与治疗前相比，血小板计数有显著下降，但在其他评估的血细胞中未发现统计学显著差异。 结论：阿达木单抗治疗对炎症性疾病HS的全身炎症标志物没有显著影响。需要更多研究来评估阿达木单抗对HS中这些标志物的影响。
J Eur Acad Dermatol Venereol. 2022-9
Eur Rev Med Pharmacol Sci. 2023-10
Zotero 插件